Average Insider

Where insiders trade, we follow

$ONCY
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
Healthcare
Sector
Biotechnology
Industry
Jared Kelly
CEO
28
Employees
$0.96
Current Price
$100.36M
Market Cap
52W Low$0.33
Current$0.9653.5% above low, 46.5% below high
52W High$1.51

Insider Activity Statistics

Aggregated buying and selling activity by time period
PeriodTypeInsidersTransactionsValueSharesBuy/Sell Ratio
1 weekBuys00---
Sells00--
2 weeksBuys00---
Sells00--
1 monthBuys00---
Sells00--
2 monthsBuys00---
Sells00--
3 monthsBuys22$15,148.0015,050All Buys
Sells00--
See activity going back 12 months โ€” create a free account

Insider Transactions

Recent purchases and sales by company insiders
DateInsiderTypeSharesPriceValueActions
Mar 11, 2026
Parsons James T.
Director
Purchase10,000$1.03$10,300.00View Details
Mar 12, 2026
Kelly Jared
Director
Purchase5,050$0.96$4,848.00View Details
12 more transactions available โ€” create a free account to see 12 months of history

Upcoming Earnings

Scheduled earnings reports
No upcoming earnings scheduled

Past Earnings

Historical earnings results
May 12, 2026
EPS
EstimatedN/A
ActualN/A
Revenue
EstimatedN/A
ActualN/A
Mar 27, 2026
EPS
Estimated-$0.06
ActualN/A
Revenue
EstimatedN/A
ActualN/A
Mar 20, 2026
EPS
Estimated-$0.06
ActualN/A
Revenue
EstimatedN/A
ActualN/A
Mar 13, 2026
EPS
Estimated-$0.06
ActualN/A
Revenue
EstimatedN/A
ActualN/A
Mar 6, 2026
EPS
Estimated-$0.06
ActualN/A
Revenue
EstimatedN/A
ActualN/A
3 more earnings records available โ€” create a free account to see 12 months of history

Related Activity

Cross-company insider connections and cluster buy signals
Version: v26.5.1